Wanbury Limited has informed the Exchange regarding a press release dated Jun 27, 2025, titled "Wanbury Limited launches Iron Supplement 'Wanbury CRED' to combat Anemia with Superior safety and absorption.".
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wanbury Limited launched 'Wanbury C RED', a novel liposomal iron supplement designed to treat anemia, on June 26, 2025, initially in North and South India with plans for a Pan-India rollout. The product uses liposomal technology that offers better absorption, no metallic aftertaste, no constipation risk, and no calcium chelation, making it safer for pregnant women and iron-deficient individuals. The company reported strong early uptake and positive feedback from doctors and healthcare professionals in the launch regions. Wanbury highlighted that India's iron supplement market is growing steadily, with anemia affecting over 40% of the population. The launch builds on the company's earlier success with brand 'C Pink' (which was divested to Cipla) and aims to strengthen its gynaecology and nutraceuticals portfolio.
Positive near-term sentiment as the new product targets a large and growing market, but the announcement lacks revenue projections or order values, so material impact on stock price is likely limited until sales traction is demonstrated.